The return of early-stage IPOs, like Scribe's, indicates growing investor risk appetite. However, companies that go public prematurely, as SANA Biotechnologies did, often struggle long-term as their valuations become subject to market whims before they have a solid clinical story to stand on.

The recent biotech market downturn raised the bar for going public. Unlike the 2020-2021 period where preclinical companies IPO'd, today's successful offerings are from companies with mid-to-late-stage clinical programs. This de-risked profile is necessary to attract both specialist and crucial generalist investors back to the sector.

Unlike the 2020-2022 bubble, the expected wave of biotech IPOs features mid-to-late-stage companies with de-risked assets. The market's recent discipline, forced by a tough funding environment, has created a backlog of high-quality private companies that are better prepared for public markets than their predecessors.

The reopening of the biotech IPO market is fragile. A key risk identified by investors is a series of failed IPOs, which could halt the sector's positive momentum. Consequently, there is intense pressure on bankers and VCs to exhibit "quality discipline," ensuring that only the most mature and high-potential companies go public first to build a track record of success.

The biotech IPO window is neither shut nor wide open. Record-breaking raises like Parabolus Medicine's $771M IPO show a strong appetite for high-quality, data-backed companies. This selective, data-driven environment is considered a healthy and sustainable "Goldilocks" market that stakeholders have long desired.

The current IPO window sees companies with significant clinical data going public. The previously closed market forced them to advance programs with private funding, resulting in higher-quality offerings compared to the pre-clinical companies that IPO'd during the last boom.

The 2026 biotech IPO market is outpacing 2025, but the focus on companies with late-stage clinical data, like Cardigan, indicates a mature and rational market rather than the speculative, preclinical bubbles of the past.

The closed IPO window forced many private biotech companies to achieve significant clinical milestones, like Phase 2 proof-of-concept, while still private. This has created an unusual cohort of well-seasoned, de-risked companies with attractive valuations, poised to be highly appealing to public investors.

The successful, upsized IPOs of several biotechs suggest the market is receptive but cautious. Investors are prioritizing companies with lower-risk propositions, such as those building on validated biological mechanisms or advancing into late-stage trials, over purely speculative, early-stage science.